A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 23, 2015

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions
Solid Tumor
Interventions
DRUG

Oraxol

"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"

Trial Locations (8)

114

Tri-Service General Hospital, Taipei

3168

Monash Medical Centre, Clayton

23561

Taipei Medical University Shuang Ho Hospital, New Taipei City

Unknown

Auckland City Hospital, Auckland

Dunedin Hospital, Dunedin

Wellington Regional Hospital, Wellington

Lotung Poh-Ai Hospital, Yilan

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Zenith Technology Corporation Limited

INDUSTRY

collaborator

PharmaEssentia

INDUSTRY

lead

Athenex, Inc.

INDUSTRY